FrancophonIA/ELRC3.0 huggingface dataset:
English: The most serious reported adverse reactions are anaphylactic reaction/shock, atypical fractures of the femur, osteonecrosis of the jaw, gastrointestinal irritation, and ocular inflammation (see paragraph “Description of selected adverse reactions” and section 4.4).Treatment was most frequently associated with a decrease in serum calcium to below normal range (hypocalcaemia), followed by dyspepsia.
Croatian: Najozbiljnije prijavljene nuspojave su anafilaktička reakcija/šok, atipični prijelomi bedrene kosti, osteonekroza čeljusti, gastrointestinalna iritacija i upala oka (vidjeti odlomak „Opis odabranih nuspojava“ i dio 4.4).
English: • gallstones
Croatian: • žučni kamenci
English: A statistically significant improvement in bone pain score was shown for Bondronat 50 mg compared to placebo.
Croatian: Bondronat 50 mg je u usporedbi s placebom pokazao statistički značajno poboljšanje rezultata kod boli u kostima.
English: You may have early signs of severe jaw problems (necrosis
Croatian: To mogu biti rani znakovi teških problema čeljusne kosti
English: In most patients with severe hypercalcaemia (albumin-corrected serum calcium* 3 mmol/l or 12 mg/dl) 4 mg is an adequate single dose.
Croatian: U većine bolesnika s teškom hiperkalcijemijom (kalcij u serumu korigiran albuminom* ≥ 3 mmol/l ili  12 mg/dl) prikladna je jednokratna doza od 4 mg.
English: Nervous system disorders
Croatian: Endokrini poremećaji poremećaj paratiroidnih žlijezda
English: NAME OF THE MEDICINAL PRODUCT AND ROUTE(S) OF ADMINISTRATION Bondronat 2 mg concentrate for solution for infusion ibandronic acid
Croatian: NAZIV LIJEKA I PUT(EVI) PRIMJENE LIJEKA Bondronat 2 mg koncentrat za otopinu za infuziju ibandronatna kiselina i.v. primjena
English: Diarrhoea, vomiting, dyspepsia, gastrointestinal pain, tooth disorder
Croatian: Poremećaji probavnog sustava proljev, povraćanje, dispepsija, gastrointestinaln a bol, poremećaji zuba gastroenteritis, gastritis, ulceracija usta, disfagija, heilitis
English: Gastroenteritis, gastritis, mouth ulceration, dysphagia, cheilitis
Croatian: Poremećaji probavnog sustava proljev, povraćanje, dispepsija, gastrointestina lna bol, poremećaji zuba gastroenteritis, gastritis, ulceracija usta, disfagija, heilitis
English: NAME OF THE MEDICINAL PRODUCT AND ROUTE(S) OF ADMINISTRATION Bondronat 6 mg concentrate for solution for infusion ibandronic acid
Croatian: NAZIV LIJEKA I PUT(EVI) PRIMJENE LIJEKA Bondronat 6 mg koncentrat za otopinu za infuziju ibandronatna kiselina i.v. primjena
English: Cases of ONJ have been reported in the post marketing setting for ibandronic acid.
Croatian: Slučajevi osteonekroze čeljusti prijavljeni su kod primjene ibandronatne kiseline nakon njezina stavljanja u promet.
English: MARKETING AUTHORISATION NUMBER(S) EU/1/96/012/009
Croatian: BROJ(EVI) ODOBRENJA ZA STAVLJANJE LIJEKA U PROMET EU/1/96/012/009
English: • if you have or ever had low calcium in your blood Do not take this medicine if any of the above apply to you.
Croatian: • ako imate ili ste ikada imali nisku razinu kalcija u krvi.
English: MARKETING AUTHORISATION NUMBER(S) EU/1/96/012/004
Croatian: BROJ(EVI) ODOBRENJA ZA STAVLJANJE LIJEKA U PROMET EU/1/96/012/004
English: angioedema†, anaphylactic reaction/shock†
Croatian: Poremećaji imunološkog sustava preosjetljivost bronhospazam angioedem†, anafilaktička reakcija/šok†*
English: This is because it can cause irritation, inflammation or ulcers in your food pipe/gullet (oesophagus).
Croatian: Važno je da Bondronat uzimate u pravo vrijeme i na pravi način jer može izazvati iritaciju, upalu ili vrijed jednjaka (ezofagusa).
English: For patients with moderate renal impairment (CLcr ≥30 and <50 mL/min) or severe renal impairment (CLcr <30 mL/min) being treated for the prevention of skeletal events in patients with breast cancer and metastatic bone disease the following dosing recommendations should be followed:
Croatian: Za bolesnike s rakom dojke i koštanim metastazama te s umjerenim oštećenjem bubrega (klirens kreatinina ≥30 i <50 ml/min) ili teškim oštećenjem bubrega (klirens kreatinina < 30 ml/min) koji se liječe radi sprječavanja koštanih poremećaja, treba slijediti sljedeće preporuke za doziranje:
English: Silica, anhydrous colloidal
Croatian: Volumen infuzije1 i vrijeme2
English: Common (may affect up to 1 in 10 people)
Croatian: Česte (mogu se javiti kod manje od 1 na 10 osoba)
English: Lactose monohydrate Povidone
Croatian: Atipični lomovi bedrene kosti
English: • problems with your parathyroid gland
Croatian: • problemi s paratiroidnom žlijezdom
English: Blood parathyroid hormone increased
Croatian: Pretrage povećana razina hormona paratiroidne žlijezde u krvi
English: STATEMENT OF ACTIVE SUBSTANCE(S) Each vial contains 6 mg of ibandronic acid (as sodium monohydrate).
Croatian: TVARI Jedna bočica sadrži 6 mg ibandronatne kiseline (u obliku natrijevog hidrata).
English: = serum calcium (mg/dl) + 0.8 x [4 - albumin (g/dl)] To convert the albumin-corrected serum calcium in mmol/l value to mg/dl, multiply by
Croatian: = kalcij u serumu (mmol/l) - [0,02 x albumin (g/l)] ili kalcij u serumu korigiran albuminom (mg/dl)
English: Rash, alopecia
Croatian: egzacerbacija astme
English: STATEMENT OF ACTIVE SUBSTANCE(S) Each film-coated tablet contains 50 mg of ibandronic acid (as sodium monohydrate).
Croatian: TVARI Jedna filmom obložena tableta sadrži 50 mg ibandronatne kiseline (u obliku natrijevog hidrata).
English: Dosage: Prevention of Skeletal Events in Patients with Breast Cancer and Bone Metastases The recommended dose for prevention of skeletal events in patients with breast cancer and bone metastases is 6 mg intravenously given every 3-4 weeks.
Croatian: Preporučena doza za sprječavanje koštanih poremećaja u bolesnika s rakom dojke i koštanim metastazama iznosi 6 mg intravenski svaka 3 - 4 tjedna.
English: STATEMENT OF ACTIVE SUBSTANCE(S) Each vial contains 2 mg of ibandronic acid (as sodium monohydrate).
Croatian: TVARI Jedna bočica sadrži 2 mg ibandronatne kiseline (u obliku natrijevog hidrata).
English: WHO performance score *
Croatian: Opće stanje prema SZO *
English: For patients with moderate renal impairment (CLcr ≥30 and <50 mL/min) or severe renal impairment (CLcr <30 mL/min) being treated for the prevention of skeletal events in patients with breast cancer and metastatic bone disease the following dosing recommendations should be followed (see section
Croatian: Za bolesnike s rakom dojke i koštanim metastazama te s umjerenim oštećenjem bubrega (klirens kreatinina ≥ 30 i < 50 ml/min) ili teškim oštećenjem bubrega (klirens kreatinina < 30 ml/min) koji se liječe radi sprječavanja koštanih poremećaja, treba slijediti sljedeće preporuke za doziranje (vidjeti dio 5.2):
English: Skin disorder, ecchymosis
Croatian: Poremećaji kože i potkožnog tkiva poremećaj kože, ekhimoza osip, alopecija
English: This is to check that you are being given the right amount of this medicine.
Croatian: Prijavljivanjem nuspojava možete pridonijeti u procjeni sigurnosti ovog lijeka.
English: NAME OF THE MEDICINAL PRODUCT Bondronat 6 mg concentrate for solution for infusion ibandronic acid
Croatian: Uputa o lijeku: Informacije za bolesnika Bondronat 6 mg koncentrat za otopinu za infuziju ibandronatna kiselina
English: NAME OF THE MEDICINAL PRODUCT Bondronat 2 mg concentrate for solution for infusion ibandronic acid
Croatian: Uputa o lijeku: Informacije za bolesnika Bondronat 2 mg koncentrat za otopinu za infuziju ibandronatna kiselina
English: (dead bone tissue) in the jaw bone)
Croatian: (nekroze, tj. odumiranja koštanog tkiva).
English: Cellulose, microcrystalline Crospovidone Stearic acid
Croatian: Jezgra tablete: laktoza hidrat povidon celuloza, mikrokristalična krospovidon stearatna kiselina silicijev dioksid, koloidni, bezvodni
English: Pharmaceutical Form Route of Administration
Croatian: (Zaštićeni) naziv Doza Farmaceutski Oblik
English: Strength
Croatian: Veličina pakovanja
English: The recommended dose is one tablet once a day.
Croatian: Preporučena doza je jedna tableta jednom na dan.
English: Zontivity vorapaxar
Croatian: Zontivity vorapaksar
English: This summary was last updated in 07-2016.
Croatian: Ovaj je sažetak posljednji put ažuriran: 07.2016.
English: The full EPAR and risk management plan summary for Zontivity can be found on the Agency's website: ema.europa.eu/Find medicine/Human medicines/European public assessment reports.
Croatian: Cjelovito Europsko javno izvješće o ocjeni dokumentacije o lijeku (EPAR) za lijek Zontivity nalazi se na internetskim stranicama Agencije: ema.europa.eu/Find medicine/Human medicines/European public assessment reports.
English: What measures are being taken to ensure the safe and effective use of Zontivity?
Croatian: Koje se mjere poduzimaju kako bi se osigurala sigurna i učinkovita primjena lijeka Zontivity?
English: The European Commission granted a marketing authorisation valid throughout the European Union for Zontivity on 19 January 2015.
Croatian: Europska komisija izdala je odobrenje za stavljanje u promet koje je za lijek Zontivity na snazi u Europskoj uniji od 19. siječnja 2015.
English: Nearly all patients also took aspirin and/or another medicine to prevent atherothrombotic events, and were treated for at least a year.
Croatian: Gotovo su svi bolesnici također uzimali aspirin i/ili drugi lijek kako bi spriječili aterotrombotske događaje i liječeni su najmanje godinu dana.
English: Other information about Zontivity
Croatian: Ostale informacije o lijeku Zontivity
English: It is not intended to provide practical advice on how to use Zontivity.
Croatian: Svrha sažetka nije davati praktične savjete o korištenju lijeka Zontivity.
English: This is a summary of the European public assessment report (EPAR) for Zontivity.
Croatian: Ovo je sažetak europskoga javnog izvješća o ocjeni dokumentacije (EPAR) za lijek Zontivity.
English: What is Zontivity and what is it used for?
Croatian: Što je Zontivity i za što se koristi?
English: Why is Zontivity approved?
Croatian: Zašto je Zontivity odobren?
English: Zontivity is available as tablets (2 mg) and can only be obtained with a prescription.
Croatian: Zontivity je dostupan u obliku tableta (2 mg) i izdaje se samo na liječnički recept.
English: There are limited data on the use of Zontivity for longer than 2 years; therefore, after 2 years of treatment, the benefits and risks of Zontivity should be re-evaluated in individual patients by the treating doctor.
Croatian: Dostupni su samo ograničeni podaci o primjeni lijeka Zontivity za razdoblja dulja od 2 godine, stoga nakon dvije godine terapije liječnik koji provodi terapiju treba ponovno ocijeniti koristi i rizike lijeka Zontivity za pojedinog bolesnika.
English: It must also not be used in patients who have had intracranial haemorrhage (bleeding in the brain) or who are actively bleeding, nor in patients with severely reduced liver function.
Croatian: Također se ne smije koristiti u bolesnika koji su imali intrakranijalno krvarenje (krvarenje u mozgu) ili koji su aktivno krvarili, kao ni u bolesnika s ozbiljnim smanjenjem funkcije jetre.
English: Recommendations and precautions to be followed by healthcare professionals and patients for the safe and effective use of Zontivity have been included in the summary of product characteristics and the package leaflet.
Croatian: Preporuke i mjere opreza kojih se zdravstveni radnici i bolesnici trebaju pridržavati u cilju sigurne i učinkovite primjene lijeka Zontivity nalaze se u sažetku opisa svojstava lijeka i u uputi o lijeku.
English: Blocking the PAR-1 receptor stops the platelets becoming sticky, reducing the risk of a blood clot forming and helping to prevent a stroke or heart attack.
Croatian: Blokiranje PAR-1 receptora sprječava ljepljivost trombocita, što smanjuje rizik od formiranja krvnih ugrušaka i pomaže u sprječavanju moždanog ili srčanog udara.
English: Vorapaxar blocks the PAR-1 receptors (known as ‘thrombin receptors') on the surface of the platelets.
Croatian: Vorapaksar inhibira PAR-1 receptore (zvane „receptori trombina“) na površini trombocita.
English: The Agency's Committee for Medicinal Products for Human Use (CHMP) decided that Zontivity's benefits are greater than its risks and recommended that it be approved for use in the EU.
Croatian: Odbor za lijekove za humanu uporabu (CHMP) pri Agenciji odlučio je da koristi lijeka Zontivity nadmašuju s njim povezane rizike te je preporučio njegovo odobrenje za korištenje u Europskoj uniji.
English: What are the risks associated with Zontivity?
Croatian: Koji su rizici povezani s lijekom Zontivity?
English: This means that it helps to prevent blood clots from forming.
Croatian: To znači da sprečava formiranje krvnih ugrušaka.
English: Zontivity contains the active substance vorapaxar.
Croatian: Zontivity sadrži djelatnu tvar vorapaksar.
English: Zontivity was more effective than placebo at reducing the occurrence of atherothrombotic events.
Croatian: Utvrđeno je da je lijek Zontivity bio djelotvorniji od placeba u smanjivanju nastupanja aterotrombotskih događaja.
English: Zontivity must not be used together with prasugrel or ticagrelor, two other medicines that help to prevent platelets from sticking together.
Croatian: Lijek Zontivity ne smije se koristiti zajedno s prasugrelom ili tikagrelorom, dvama drugim lijekovima koji pomažu u sprječavanju međusobnog lijepljenja trombocita.
English: The main measure of effectiveness was based on the number of patients having an ‘event' such as a heart attack or stroke, or dying from cardiovascular disease (problems affecting the heart and blood vessels).
Croatian: Glavna mjera djelotvornosti temeljila se na broju bolesnika koji su pretrpjeli „događaj“ poput infarkta miokarda ili moždanog udara ili su umrli od kardiovaskularne bolesti (problema koji zahvaćaju srce i krvne žile).
English: For patients with peripheral arterial disease, treatment with Zontivity may be started at any time.
Croatian: Bolesnici koji boluju od bolesti perifernih arterija mogu započeti terapiju lijekom Zontivity u bilo kojem trenutku.
English: However, as patients with peripheral arterial disease have a high risk of atherothrombotic events and the treatment options for prevention of these events are limited, the CHMP considered that Zontivity's benefits are greater than its risks for this condition.
Croatian: Međutim, budući da su bolesnici koji boluju od bolesti perifernih arterija podložni visokom riziku od aterotrombotskih događaja te da su terapijske opcije za sprječavanje tih događaja vrlo ograničene, CHMP je zaključio da koristi lijeka Zontivity nadmašuju s njim povezane rizike u pogledu ove bolesti.
English: Heart attacks and some types of strokes result from blood clots in arteries.
Croatian: Infarkt miokarda i neki tipovi moždanih udara posljedica su krvnih ugrušaka u arterijama.
English: Regarding Zontivity's safety profile, the CHMP was concerned about the risk of bleeding in patients taking Zontivity on top of their standard therapy, particularly serious bleeding which was more frequent in patients with a history of stroke.
Croatian: Vezano uz sigurnosni profil lijeka Zontivity, CHMP je izrazio zabrinutost u vezi s rizikom povezanim s krvarenjem u bolesnika koji uzimaju Zontivity uz standardnu terapiju, posebice s ozbiljnim krvarenjem koje je češće u bolesnika s anamnezom moždanog udara.
English: In patients with peripheral arterial disease, the data showed a benefit for patients taking Zontivity, although the number of atherothrombotic events reported during the main study was not large enough to enable conclusive results.
Croatian: Podaci govore da se uzimanje lijeka Zontivity pokazalo korisnim za bolesnike koji boluju od bolesti perifernih arterija, premda broj aterotrombotskih događaja prijavljenih tijekom glavnog ispitivanja nije bio dovoljno velik za omogućavanje jasnih rezultata.
English: For patients who have had a heart attack, treatment with Zontivity should start from 2 weeks after and preferably within one year of the occurrence of the heart attack.
Croatian: Za bolesnike koji su pretrpjeli infarkt miokarda terapiju lijekom Zontivity treba započeti 2 tjedna nakon i po mogućnosti unutar godine dana od nastupanja infarkta miokarda.
English: In this group, 8.5% of patients (719 out of 8,458 patients) treated with Zontivity had an atherothrombotic event, compared with 10.3% of patients (867 out of 8,439 patients) on placebo.
Croatian: U ovoj grupi 8,5 % bolesnika (719 od 8 458 bolesnika) liječenih lijekom Zontivity imalo je aterotrombotski događaj, u usporedbi s 10,3% bolesnika (867 od 8 439 bolesnika) koji su uzimali placebo.
English: Thrombin is one of the substances involved in the clotting process, and when it attaches to the PAR-1 receptor it causes the platelets to become ‘sticky', helping the blood clot to form.
Croatian: Trombin je jedna od tvari uključenih u postupak grušanja i prilikom vezivanja na PAR-1 uzrokuje „ljepljivost“ trombocita te time pomaže u grušanju krvi.
English: The most common side effect with Zontivity (which may affect up to 1 in 10 people) is bleeding, particularly nosebleed.
Croatian: Najčešće nuspojave lijeka Zontivity (mogu se javiti u više od 1 na 10 osoba) jesu krvarenje, posebice epistaksa (krvarenje iz nosa).
English: For more information about treatment with Zontivity, read the package leaflet (also part of the EPAR) or contact your doctor or pharmacist.
Croatian: Više informacija o terapiji lijekom Zontivity pročitajte u uputi o lijeku (također dio EPAR-a), odnosno obratite se svom liječniku ili ljekarniku.
English: It is given in combination with aspirin (acetylsalicylic acid) and where appropriate with a third medicine, clopidogrel, both of which also help prevent atherothrombotic events.
Croatian: Primjenjuje se u kombinaciji s aspirinom (acetilsalicilnom kiselinom) i kada je potrebno, s klopidogrelom (trećim lijekom), od kojih oba sprječavaju i aterotrombotske događaje.
English: The benefits of Zontivity were clearest in a group of 16,897 patients who had had a heart attack, but had no history of stroke or transient ischaemic attack (so-called ‘mini stroke').
Croatian: Koristi lijeka Zontivity bile su najočitije u podgrupi od 16 897 bolesnika koja je imala infarkt miokarda, ali nije imala anamnezu moždanog udara ili prolaznog ishemijskog napadaja (tzv. „mali moždani udar“).
English: Overall, 9.5% of patients (1,259 out of 13,225 patients) taking Zontivity had an atherothrombotic event compared with 10.7% (1,417 out of 13,224 patients) of patients taking placebo.
Croatian: Ukupno je 9,5 % bolesnika (1 259 od 13 225 bolesnika) koji su uzimali lijek Zontivity pretrpjelo aterotrombotski događaj, u usporedbi s 10,7 % (1 417 od 13 224 bolesnika) koji su uzimali placebo.
English: Zontivity was compared with placebo (a dummy treatment) in a main study involving over 26,000 adults who had had a heart attack or other atherothrombotic event or who had peripheral arterial disease.
Croatian: Zontivity je uspoređen s placebom (prividno liječenje) u glavnom ispitivanju koje je obuhvatilo više od 26 000 odraslih osoba koje su imale infarkt miokarda ili drugi aterotrombotski događaj ili koje boluju od bolesti perifernih arterija.
English: Zontivity must not be used in patients who have had a stroke or mini stroke.
Croatian: Lijek Zontivity ne smije se koristiti u bolesnika koji su imali moždani udar ili mali moždani udar.
English: How does Zontivity work?
Croatian: Kako djeluje Zontivity?
English: The active substance in Zontivity, vorapaxar, is an inhibitor of platelet aggregation.
Croatian: Djelatna tvar lijeka Zontivity, vorapaksar, inhibitor je agregacije trombocita.
English: The medicine has been shown to be beneficial in reducing the number of atherothrombotic events in patients who had had a heart attack.
Croatian: Dokazane su koristi lijeka u smanjivanju broja aterotrombotskih događaja u bolesnika koji su imali infarkt miokarda.
English: Zontivity is a medicine used to reduce the occurrence of atherothrombotic events (problems caused by blood clots and hardening of the arteries) such as heart attacks or strokes in adult patients who have already had a heart attack or who have peripheral arterial disease (problem with blood flow in the arteries) with symptoms.
Croatian: Zontivity je lijek koji se koristi za smanjivanje aterotrombotskih događaja (problema uzrokovanih krvnim ugrušcima i očvršćivanjem arterija) poput daljnjih infarkta miokarda ili moždanih udara u odraslih bolesnika s anamnezom infarkta miokarda ili u bolesnika koji boluju od bolesti perifernih arterija (problemi s protokom krvi u arterijama) sa simptomima.
English: For practical information about using Zontivity, patients should read the package leaflet or contact their doctor or pharmacist.
Croatian: Praktične informacije o korištenju lijeka Zontivity pročitajte u uputi o lijeku, odnosno obratite se svom liječniku ili ljekarniku.
English: Among patients with peripheral arterial disease, 10.9% (177 out of 1,622 patients) taking Zontivity had an atherothrombotic event compared with 12.5% (206 out of 1,651 patients) of patients taking placebo.
Croatian: Ukupno je 10,9 % bolesnika (177 od 1 622 bolesnika) koji uzimaju lijek Zontivity pretrpjelo aterotrombotski događaj, u usporedbi s 12,5 % (206 od 1 651 bolesnika) koji su uzimali placebo.
English: What benefits of Zontivity have been shown in studies?
Croatian: Koje su koristi lijeka Zontivity utvrđene u ispitivanjima?
English: It therefore considered it appropriate to restrict the use to patients who have not had a stroke.
Croatian: CHMP je stoga zaključio da je primjereno ograničiti primjenu na bolesnike koji nisu imali moždani udar.
English: When the blood clots, components in the blood called platelets stick together.
Croatian: Prilikom grušanja krvi dolazi do nakupljanja posebnih stanica u krvi zvanih trombociti.
English: It is given in combination with either aspirin or, where appropriate, with clopidogrel.
Croatian: Lijek se daje u kombinaciji s aspirinom ili klopidogrelom ako je potrebno.
English: How is Zontivity used?
Croatian: Kako se Zontivity koristi?
English: It is given in combination with aspirin and where appropriate, clopidogrel.
Croatian: Lijek se daje u kombinaciji s aspirinom i klopidogrelom ako je potrebno.
English: MA (EU) number
Croatian: Broj EU odobrenja Zaštićeno ime
English: This will help protect against coccidiosis.
Croatian: To će pomoći u zaštiti od kokcidioze.
English: Hands and equipment should be washed and disinfected after use.
Croatian: Nakon uporabe potrebno je oprati i dezinficirati ruke i opremu.
English: The full EPAR for Evalon can be found on the Agency's website: ema.europa.eu/Find medicine/Veterinary medicines/European public assessment reports.
Croatian: Cjeloviti EPAR za VMP Evalon nalazi se na internetskim stranicama Agencije: ema.europa.eu/Find medicine/Veterinary medicines/European public assessment reports.
English: In the future if the animals are exposed to the same Eimeria species the immune system will be able to respond more quickly.
Croatian: Ako životinje u budućnosti budu izložene istim vrstama parazita Eimeria, imunosni sustav moći će brže reagirati.
English: Protection starts at 3 weeks after vaccination and lasts until 60 weeks after vaccination.
Croatian: Zaštita nastupa tri tjedna nakon cijepljenja i traje 60 tjedana nakon cijepljenja.
English: Evalon is a vaccine.
Croatian: Evalon je cjepivo.
English: The vaccine suspension should be diluted with the solvent and water according to dosing instructions and sprayed onto the birds so that each bird receives one dose.
Croatian: Suspenziju cjepiva potrebno je razrijediti otapalom i vodom u skladu s uputama o doziranju i raspršiti na ptice tako da svaka ptica primi jednu dozu.
English: The birds consume the vaccine when preening their feathers.
Croatian: Ptice konzumiraju cjepivo kada dotjeruju svoje perje.
English: Evalon is available as a suspension and solvent and can only be obtained with a prescription.
Croatian: Evalon je dostupan kao suspenzija i otopina i izdaje se samo na recept.
English: The withdrawal period for meat and eggs from chickens treated with Evalon is ‘zero' days, which means there is no mandatory waiting time.
Croatian: Razdoblje karencije za meso i jaja pilića liječenih VMP-om Evalon iznosi „nula” dana, drugim riječima, nema obveznog perioda čekanja.